DEC 23, 2019 9:49 AM PST

Long awaited at-home test gives hemophiliacs peace of mind

WRITTEN BY: Tara Fernandes

Haemophilia is a genetically-inherited condition that severely affects an individual’s ability to stop bleeding. Blood clotting is a natural protective response, orchestrated by circulating proteins known as clotting factors.

In the event of an internal or external bleed, a cascade of hematological events is quickly triggered to minimize damage. Firstly, blood vessels shrink to constrict blood flow. Next, blood cells called platelets are activated and interact with other blood proteins, such as fibrin, to create a mesh dam-like structure. The video below highlights the complex biology of the clotting process.

 

Managing hemophilia involves a delicate balance of measuring a patient’s coagulation status, or the ability of their blood to form a clot, and then administering an appropriate therapeutic dose of a clotting factor. If the coagulation status is too low, the patient risks massive internal bleeding. Too high, and blood clots can spontaneously form in veins and arteries, spiking the risk of a heart attack or stroke.

Japanese pharmaceutical giant, Takeda, in partnership with technology developed by Dutch biotech, Enzyre, is creating the first diagnostic test for hemophilia patients -- allowing them to measure their coagulation status accurately from the comfort of their own homes.

This development is a long time coming for the 400,000 people living with hemophilia around the world, who mostly manage their condition on their own, only seeking medical care when urgently required. An at-home diagnostic tool can provide much greater control over managing their health effectively.

The device, known as the ENZYPAD (pictured below), painlessly takes a sample of blood from the patient and runs the test on a microfluidic cartridge. The test results are instantly available to patients, caregivers and their physicians via a mobile app. With this life-changing technology, patients can confidently lead active lifestyles without worrying about their risk of bleeding or having to perform traditional blood tests at a hospital.

Inspired by creating solutions to improve hemophiliacs’ quality of life, Dirk Pollet, CEO of Enzyre said, “With our proprietary technology, we aim to provide hemophilia patients and their caregivers with peace of mind by allowing them to monitor coagulation status at home. Ultimately we'd like to empower these patients to live a normal life.”

Other pharmaceutical companies, such as Pfizer and Sangamo Therapeutics are also developing clinical strategies to support hemophiliacs, by taking a gene therapy approach. They recently disclosed some promising results from a gene therapy clinical trial, in which the gene for Factor VIII (the missing link for patients with Hemophilia A) was delivered to the liver of patients. This stimulates the liver to act as a factory for Factor VIII, bringing circulating levels of the clotting factor up towards the normal range and protecting against bleeding.

With improved point-of-care diagnostics and next-generation therapies for hemophilia just around the corner, families living with hemophilia can expect much more peace of mind.



Sources: Fierce Biotech, NHS, Hemophilia News Today.

 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
JUN 13, 2022
Microbiology
Fight Antimicrobial Resistance
JUN 13, 2022
Fight Antimicrobial Resistance
Carbapenem antibiotics are one of the few remaining antibiotics effective in treating ESBL infections or MDRO. Howe ...
JUL 14, 2022
Clinical & Molecular DX
A magnetic bead for every need: Expanding applications with conjugated magnetic beads
JUL 14, 2022
A magnetic bead for every need: Expanding applications with conjugated magnetic beads
Magnetic beads (or superparamagnetic particles) can be used for the isolation and purification of cells, nucleic acids, ...
JUL 12, 2022
Microbiology
New Findings May Lead to Fibromyalgia Diagnostics & Treatments
JUL 12, 2022
New Findings May Lead to Fibromyalgia Diagnostics & Treatments
Many fibromyalgia patients spent years waiting for clinicians to acknowledge their condition, and researchers have been ...
JUL 21, 2022
Technology
Parents Underestimate the Effect of Screen Time on Children's Eye Health
JUL 21, 2022
Parents Underestimate the Effect of Screen Time on Children's Eye Health
The oft-debated question of “how much time should my child spend looking at a screen” has become incredibly ...
JUL 25, 2022
Cancer
Does the Secret to Immunotherapy Lie in...Poop?
JUL 25, 2022
Does the Secret to Immunotherapy Lie in...Poop?
Advancements in immunotherapy have proven instrumental in reshaping the face of cancer research in recent years.  W ...
JUL 26, 2022
Cardiology
Only 20% of Americans Have Optimal Heart Health
JUL 26, 2022
Only 20% of Americans Have Optimal Heart Health
According to the AHA's updated metrics, only 1 in 5 Americans has "high" cardiovascular health.
Loading Comments...